PIK3CA and breast carcinoma: Studies reported pCR benefits of 44.4% (n=8/18) in TNBC patients treated with NAC TP than 0% (n=0/9) in Luminal A [69], 8.9% (n=56/632) in ER+ breast cancer patients treated with NAC TA than 19.8% (n=75/378) in ER− patients [36], and 24.7% (n=55/223) in breast cancer patients with wildtype PIK3CA gene treated with NAC TA than 11.7% (n=11/94) in mutated PIK3CA [106].